ArticleFrontiers in immunology2022

Inhibiting EGFR/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A.

Jieun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.